Scholarlink

Background <p>Few comprehensive studies have examined the associations of the ABO blood group with survival outcomes for patients with resected pancreatic cancer, overall and by adjuvant chemotherapy regimens.</p> Methods <p>This multicenter study enrolled 1153 patients with resected pancreatic cancer. The hazard ratios (HRs) for disease-free and pancreatic cancer-specific survival were calculated with adjustment for potential confounders, including <i>KRAS</i> mutation and CDKN2A (p16), TP53, and SMAD4 expression, using the Cox proportional hazards regression model. Blood group antigen expression in tumors was immunohistochemically assessed.</p> Results <p>The ABO blood group was not associated with disease-free or pancreatic cancer-specific survival (<i>P</i> &gt; 0.90). For pancreatic cancer-specific survival, blood groups A, B, and AB had multivariable HRs of 0.97 (95% confidence interval [CI], 0.81–1.15), 1.03 (95% CI, 0.83–1.26), and 0.99 (95% CI, 0.76–1.30), respectively (vs. O). The associations between ABO blood group and disease-free and pancreatic cancer-specific survival differed according to the adjuvant chemotherapy regimens (<i>P</i><sub>interaction</sub> = 0.011 and 0.008, respectively). For the patients without chemotherapy, the HRs for disease-free survival were 0.99 (95% CI, 0.69–1.41) for blood group A, 1.65 (95% CI, 1.09–2.48) for blood group B, and 1.79 (95% CI, 1.01–3.17) for blood group AB, (vs. O). For the patients receiving S-1-based chemotherapy, blood group AB (vs. O) exhibited a reverse association (HR, 0.63; 95% CI, 0.39–1.00). Similar interactions were observed when blood group antigen expression in tumors was analyzed.</p> Conclusions <p>The ABO blood group is not a prognostic biomarker in resected pancreatic cancer overall but may predict the effectiveness of adjuvant chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月2日

查看全文
  • Yosuke Inoue,
  • Manabu Takamatsu,
  • Yohei Masugi,
  • Tatsunori Suzuki,
  • Tsuyoshi Hamada,
  • Satoru Abe,
  • Kensuke Hara,
  • Yoshikuni Kawaguchi,
  • Kosuke Kobayashi,
  • Aya Maekawa,
  • Yousuke Nakai,
  • Naoki Sasahira,
  • Tsuyoshi Takeda,
  • Mariko Tanaka,
  • Yosuke Uematsu,
  • Sho Uemura,
  • Tetsuo Ushiku,
  • Mitsuhiro Fujishiro,
  • Kengo Takeuchi,
  • Minoru Kitago,
  • Kiyoshi Hasegawa,
  • Yu Takahashi,
  • Satoko Baba,
  • Shuhei Ishii,
  • Motoyoshi Iwakoshi,
  • Kikuko Kaji,
  • Kei Sakuma,
  • Noriko Koga

摘要

Background

Few comprehensive studies have examined the associations of the ABO blood group with survival outcomes for patients with resected pancreatic cancer, overall and by adjuvant chemotherapy regimens.

Methods

This multicenter study enrolled 1153 patients with resected pancreatic cancer. The hazard ratios (HRs) for disease-free and pancreatic cancer-specific survival were calculated with adjustment for potential confounders, including KRAS mutation and CDKN2A (p16), TP53, and SMAD4 expression, using the Cox proportional hazards regression model. Blood group antigen expression in tumors was immunohistochemically assessed.

Results

The ABO blood group was not associated with disease-free or pancreatic cancer-specific survival (P > 0.90). For pancreatic cancer-specific survival, blood groups A, B, and AB had multivariable HRs of 0.97 (95% confidence interval [CI], 0.81–1.15), 1.03 (95% CI, 0.83–1.26), and 0.99 (95% CI, 0.76–1.30), respectively (vs. O). The associations between ABO blood group and disease-free and pancreatic cancer-specific survival differed according to the adjuvant chemotherapy regimens (Pinteraction = 0.011 and 0.008, respectively). For the patients without chemotherapy, the HRs for disease-free survival were 0.99 (95% CI, 0.69–1.41) for blood group A, 1.65 (95% CI, 1.09–2.48) for blood group B, and 1.79 (95% CI, 1.01–3.17) for blood group AB, (vs. O). For the patients receiving S-1-based chemotherapy, blood group AB (vs. O) exhibited a reverse association (HR, 0.63; 95% CI, 0.39–1.00). Similar interactions were observed when blood group antigen expression in tumors was analyzed.

Conclusions

The ABO blood group is not a prognostic biomarker in resected pancreatic cancer overall but may predict the effectiveness of adjuvant chemotherapy.